التفاصيل البيبلوغرافية
| العنوان: |
Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial. |
| المؤلفون: |
Haidar, Ahmad1,2 ahmad.haidar@mcgill.ca, Messier, Virginie3, Legault, Laurent4, Ladouceur, Martin5,6, Rabasa‐Lhoret, Rémi3,5,7,8 |
| المصدر: |
Diabetes, Obesity & Metabolism. May2017, Vol. 19 Issue 5, p713-720. 1p. |
| مصطلحات موضوعية: |
*ARTIFICIAL pancreases, *HYPOGLYCEMIA, *TREATMENT of diabetes, *TYPE 1 diabetes, *INSULIN therapy, *GLUCAGON, *THERAPEUTICS |
| مستخلص: |
Aims To assess whether the dual-hormone (insulin and glucagon) artificial pancreas reduces hypoglycaemia compared to the single-hormone (insulin alone) artificial pancreas in outpatient settings during the day and night. Material and methods In a randomized, three-way, crossover trial we compared the dual-hormone artificial pancreas, the single-hormone artificial pancreas and sensor-augmented pump therapy (control) in 23 adults with type 1 diabetes. Each intervention was applied from 8 AM Day 1 to 8 PM Day 3 (60 hours) in outpatient free-living conditions. The primary outcome was time spent with sensor glucose levels below 4.0 mmol/ L. A P value of less than .017 was regarded as significant. Results The median difference between the dual-hormone system and the single-hormone system was −2.3% ( P = .072) for time spent below 4.0 mmol/ L, −1.3% ( P = .017) for time below 3.5 mmol/ L, and −0.7% ( P = .031) for time below 3.3 mmol/ L. Both systems reduced ( P < .017) hypoglycaemia below 4.0, 3.5 and 3.3 mmol/ L compared to control therapy, but reductions were larger with the dual-hormone system than with the single-hormone system (medians −4.0% vs −3.4% for 4.0 mmol/ L; −2.7% vs −2.2% for 3.5 mmol/ L; and −2.2% vs −1.2% for 3.3 mmol/ L). There were 34 hypoglycaemic events (<3.0 mmol/ L for 20 minutes) with control therapy, 14 with the single-hormone system and 6 with the dual-hormone system. These differences in hypoglycaemia were observed while mean glucose level was low and comparable in all interventions ( P = NS). Conclusions The dual-hormone artificial pancreas had the lowest risk of hypoglycaemia, but the differences were not statistically significant. Larger studies are needed. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
